The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Melanoma
Interventions
DRUG

Vemurafenib

Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.

Trial Locations (1)

11103

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Philip Friedlander

OTHER

NCT01942993 - The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | Biotech Hunter | Biotech Hunter